Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre

Heart

Volumn 100, Issue 3, 2014, Pages 224-230

  Douwes, Johannes M ^a   Roofthooft, Marcus T R ^a   Van Loon, Rosa L E ^a   Ploegstra, Mark Jan ^a   Bartelds, Beatrijs ^a   Hillege, Hans L ^a   Berger, Rolf M F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; LIVER ENZYME; PROSTACYCLIN; SILDENAFIL;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MALE; MONOTHERAPY; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TRANSPLANT FREE SURVIVAL; WALKING;

ADOLESCENT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CHILD; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; NETHERLANDS; PIPERAZINES; PURINES; SECONDARY CARE CENTERS; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84891789375     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304895     Document Type: Article

References (30)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. results from a national prospective registry. Ann Intern Med 1991;115:343-9.
2. Authors/Task Force MembersGalie N, Hoeper MM, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS), endorsed by the international society of heart and lung transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
3. van Loon RL, Roofthooft MT, Delhaas T, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol 2010;106:117-24.
4. Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012;125:113-22.
5. Ivy DD, Rosenzweig EB, Lemarie JC, et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010;106:1332-8.
6. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: The UK pulmonary hypertension service for children 2001-2006. Heart 2009;95:312-17.
7. van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: Does the beneficial effect persist? Am Heart J 2007;154:776-82. (Pubitemid 47429578)
8. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63. (Pubitemid 41632043)
9. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29:469-75. (Pubitemid 46372092)
10. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-10. (Pubitemid 39642293)
11. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22.
12. Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 2006;36(Suppl 3):32-8. (Pubitemid 44179779)
13. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82. (Pubitemid 36403597)
14. Borgdorff MA, Bartelds B, Dickinson MG, et al. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail 2012;14:1067-74.
15. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-13. (Pubitemid 40923321)
16. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005;100:131-8. (Pubitemid 40361605)
17. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005;111:3274-80. (Pubitemid 40875000)
18. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012;125:324-34.
19. Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart 2010;96:1401-6.
20. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8. (Pubitemid 34925627)
21. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589-96.
22. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010;122:164-72.
23. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63.
24. Casey AF, Wang X, Osterling K. Test-retest reliability of the 6-minute walk test in individuals with down syndrome. Arch Phys Med Rehabil 2012;93:2068-74.
25. U.S. Food and Drug Administration. FDA drug safety communication: FDA recommends against use of revatio (sildenafil) in children with pulmonary hypertension. 2013;2013.
26. Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the U.S. food and drug administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med 2013;187:572-5.
27. Duffels MG, Vis JC, van Loon RL, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without down's syndrome. Am J Cardiol 2009;103:1309-15.
28. Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: A 2-year study. Heart 2007;93:350-4. (Pubitemid 46579526)
29. Zijlstra WM, Douwes JM, Rosenzweig EB, et al. Transatlantic survival differences in pediatric pulmonary hypertension: Clues to A better understanding of disease characteristics and treatment. American Thoracic Society International Conference Abstracts 2013;A3285.
30. Ivy DD. 5th world symposium on pulmonary hypertension, pediatric task force, Chairman Dunbar D ivy. Nice, 2013.